Search tips
Search criteria 


Logo of ajcrLink to Publisher's site
Am J Cancer Res. 2012; 2(4): 476–477.
Published online 2012 June 28.
PMCID: PMC3410586

Annexin 1 and its evolving role in systemic carcinogenesis besides its role in the pathogenesis of breast carcinomas

I read with great interest the recent article by Wu et al in a recent issue of your esteemed journal [1]. The article is highly thought provoking. Interestingly, the past few years have seen the emergence of data that points towards the fact that annexin 1 (ANXA1) plays a significant role in systemic carcinogenesis besides its role in the pathogenesis of breast cancers.

For instance, ANXA1 enhances metastasis in urothelial carcinomas [2]. Similar effects are seen in laryngeal carcinomas where ANXA1 plays a modulatory role in tumor growth as is evident by inhibition of tumor growth in Hep-2 human larynx epidermoid carcinoma cell lines [3]. Similarly, nearly 70% of undifferentiated thyroid carcinomas demonstrate attenuated expression of ANXA1 [4]. On the contrary, up regulation of the protein is seen in papillary thyroid carcinomas.

Similarly, over expression of ANXA1 is seen in nearly 85 % of pancreatic ductal adenocarcinomas [5]. Simultaneously, decreased differentiation is seen in pancreatic adenocarcinomas that demonstrate accentuated expression of ANXA1. Similarly, ANXA1 is expressed along with peroxiredoxin 2 in the saliva of oral cancer patients [6]. Hairy cell leukemia also exhibits up regulation of ANXA1. In fact, ANXA1 serves as a remarkably specific test for hairy cell leukemia [7]. Interestingly, agents such as eurycomanone modulate ANXA1 levels and affect tumor growth in cancers such as pulmonary carcinomas [8].

Clearly, ANXA1 has a major role to play in tumor growth. Further, large scale studies are needed to further elaborate its effects.


1. Wu Y, Elshimali Y, Sarkissyan M, Mohamed H, Clayton S, Vadgama JV. Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer. Am J Cancer Res. 2012;2(1):104–15. [PMC free article] [PubMed]
2. Wu Y, Elshimali Y, Sarkissyan M, Mohamed H, Clayton S, Vadgama JV, Kang WY, Chen WT, Huang YC, Su YC, Chai CY. Overexpression of annexin 1 in the development and differentiation of urothelial carcinoma. Kaohsiung J Med Sci. 2012;28:145–150. [PubMed]
3. Silistino-Souza R, Rodrigues-Lisoni FC, Cury PM, Maniglia JV, Raposo LS, Tajara EH, Christian HC, Oliani SM. Annexin 1: differential expression in tumor and mast cells in human larynx cancer. Int J Cancer. 2007;120:2582–2589. [PubMed]
4. Petrella A, Festa M, Ercolino SF, Zerilli M, Stassi G, Solito E, Parente L. Annexin-1 downregulation in thyroid cancer correlates to the degree of tumor differentiation. Cancer Biol Ther. 2006;5:643–647. [PubMed]
5. Bai XF, Ni XG, Zhao P, Liu SM, Wang HX, Guo B, Zhou LP, Liu F, Zhang JS, Wang K, Xie YQ, Shao YF, Zhao XH. Overexpression of annexin 1 in pancreatic cancer and its clinical significance. World J Gastroenterol. 2004;10:1466–1470. [PubMed]
6. Szanto I, Mark L, Bona A, Maasz G, Sandor B, Gelencser G, Turi Z, Gallyas F. High-throughput screening of saliva for early detection of oral cancer: a pilot study. Technol Cancer Res Treat. 2012;11:181–188. [PubMed]
7. Falini B, Tiacci E, Liso A, Basso K, Sabattini E, Pacini R, Foa R, Pulsoni A, Dalla Favera R, Pileri S. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1) Lancet. 2004;363:1869–1870. [PubMed]
8. Wong PF, Cheong WF, Shu MH, Teh CH, Chan KL, AbuBakar S. Eurycomanone suppresses expression of lung cancer cell tumor markers, prohibitin, annexin 1 and endoplasmic reticulum protein 28. Phytomedicine. 2012;19:138–144. [PubMed]

Articles from American Journal of Cancer Research are provided here courtesy of e-Century Publishing Corporation